Kura Oncology price to book ratio KURA

Market value divided by the book value of the company's net assets, since 2015.

Today, Oct 23, 2026: 17.7×
10-year median: 3.0×
Against its 10-year history: 98th; percentile: 0 is its lowest day, 100 its highest
10-year range: 1.1× to 24.3×
Peer median: 2.5×

Kura Oncology's price to book ratio is 17.7× as of Oct 23, 2026.

That is above its ten-year median of 3.0×, higher than on 98% of days in the last ten years.

Over that time it ranged from 1.1× in Apr 2025 to 24.3× in Sep 2026.

The median for 10 large drugmakers of a similar size is 2.5×.

Price to book ratio over time

median 3×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	17.7×	2.8×	24.3×
2025	3.8×	1.1×	4.4×
2024	1.6×	1.6×	4.5×
2023	2.5×	1.2×	2.5×
2022	2.0×	1.5×	2.6×
2021	1.7×	1.5×	7.2×
2020	6.0×	1.6×	7.7×
2019	2.8×	2.5×	5.1×
2018	2.9×	2.5×	8.3×
2017	5.2×	2.0×	7.3×
2016	2.0×	0.7×	3.9×
2015	4.8×	2.7×	5.4×

Against its peers

Companies in Drug Manufacturers - General nearest Kura Oncology's size, closest first, today.

Company	Price to book ratio
KURAKura Oncology	17.7×
ABUSArbutus Biopharma	3.2×
COLLCollegium Pharmaceutical	2.4×
AMPHAmphastar Pharmaceuticals	1.4×
CRMDCorMedix	1.3×
OMEROmeros	n/m
ZVRAZevra Therapeutics	2.7×
IRWDIronwood Pharmaceuticals	n/m
PBYIPuma Biotechnology	4.1×
PCRXPacira BioSciences	2.2×
ANABAnaptysbio	138×
Peer median	2.5×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Kura Oncology

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.